By Kaspar van den Dries, Senior Director of Science and Innovation, Thermo Fisher Scientific
Softgels are a popular dosage form among consumers because of their easy swallowability and quick onset of action. Pharmaceutical developers often don’t consider softgels to be the best choice for prescription drug formulations, however, instead favoring tablets and hard-shell capsules. The disconnect between consumer and formulator preferences for prescription drugs may be due in part to misconceptions surrounding the development process for softgels and their perceived limitations. Here, we take a look at some common myths about softgels and explore why drug developers may want to reconsider their go-to delivery methods.